YH-53 is 3CL Protease Inhibitor with an Electrophilic Arylketone Moiety as Anti-SARS-CoV‑2 Agent. YH-53 can strongly block the SARSCoV-2 replication. X-ray structural analysis revealed that YH-53 establishes multiple hydrogen bond interactions with backbone amino acids and a covalent bond with the active site of 3CLpro. Further results from computational and experimental studies, including an in vitro absorption, distribution, metabolism, and excretion profile, in vivo pharmacokinetics, and metabolic analysis of YH-53 suggest that it has a high potential as a lead candidate to compete with COVID-19.
| Catalog Number | I038546 |
| CAS Number | 1471484-62-4 |
| Synonyms | YH-53; YH53; YH 53; |
| Molecular Formula | C30H33N5O5S |
| Purity | 98 |
| Solubility | To be determined |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | N-((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-4-methoxy-1H-indole-2-carboxamide |
| InChI | InChI=1S/C30H33N5O5S/c1-16(2)13-22(34-29(39)23-15-18-19(32-23)8-6-9-24(18)40-3)28(38)33-21(14-17-11-12-31-27(17)37)26(36)30-35-20-7-4-5-10-25(20)41-30/h4-10,15-17,21-22,32H,11-14H2,1-3H3,(H,31,37)(H,33,38)(H,34,39)/t17-,21-,22-/m0/s1 |
| InChIKey | JBLLRCOZJMVOAE-HSQYWUDLSA-N |
| SMILES | COC1=CC=CC2=C1C=C(C(N[C@@H](CC(C)C)C(N[C@H](C(C3=NC(C=CC=C4)=C4S3)=O)C[C@@H]5CCNC5=O)=O)=O)N2 |
| Reference | 1: Konno S, Kobayashi K, Senda M, Funai Y, Seki Y, Tamai I, Schäkel L, Sakata K, Pillaiyar T, Taguchi A, Taniguchi A, Gütschow M, Müller CE, Takeuchi K, Hirohama M, Kawaguchi A, Kojima M, Senda T, Shirasaka Y, Kamitani W, Hayashi Y. 3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents. J Med Chem. 2021 Jul 27. doi: 10.1021/acs.jmedchem.1c00665. Epub ahead of print. PMID: 34313428. |
